Therapeutic implications of the use of cardiac markers in acute coronary syndromes

References

• Braunwald E. Unstable angina: an etiologic approach to management. Circulation 1998; 98(21)2219–22
   PubMedGoogle Scholar
• de Boer M J, Hoorntje J C, Ottervanger J P, Reiffers S, Suryapranata H, Zijlstra F. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. J Am Coll Cardiol 1994; 23(5)1004–8
   PubMedGoogle Scholar
• Grines C L, Browne K F, Marco M D, et al. A comparison of immediate angioplasty with thrombolytic theraphy for acute myocardial infarction. N Engl J Med 1993; 328(10)673–9
   PubMed Web of Science ®Google Scholar
• A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997; 336(23)1621–8
   PubMed Web of Science ®Google Scholar
• Ohman E M, Armstrong P W, Christenson R H, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996; 335: 1331–41
   Google Scholar
• Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996; 94(6)1291–7
   PubMedGoogle Scholar
• Ramanathan K, Stewart J T, Theroux P, French J K, White H D. Admission troponin T level may predict 90 minute TIMI flow after thrombolysis. Circulation 1997; 96: 1270, (abstract)
   Google Scholar
• Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, Siegbahn A, Swahn E, Venge P, Wallentin L. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - a pilot study: BIOchemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33: 627–33
   PubMed Web of Science ®Google Scholar
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343(8893)311–22
   PubMed Web of Science ®Google Scholar
• Stenestrand U, Lindahl B, Wallentin L. Difficulties in the diagnosis and treatment of acute myocardial infarction in patients with left bundle-branch block at admission. Eur Heart J 1998; 19: 631, (Abstract supplement)
   Google Scholar
• Lindahl B, Venge P, Wallentin L. Early diagnosis and exclusion of acute myocardial infarction by biochemical monitoring. Coronary Artery Disease 1995; 6: 321–28
   PubMedGoogle Scholar
• Langer A, Goodman S, Topol E, et al. Late assessment of thrombolytic Efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol 1996; 27: 1327–32
   PubMed Web of Science ®Google Scholar
• Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996; 93: 1651–57
   PubMed Web of Science ®Google Scholar
• Antman E M, Tanasijevic M J, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–9
   PubMed Web of Science ®Google Scholar
• Terres W, Kummel P, Sudrow A, Reuter H, Meinertz T, Hamm C W. Enhanced coagulation activation in troponin T-positive unstable angina pectoris. Am Heart J 1998; 135: 281–6
   PubMedGoogle Scholar
• Jurlander B, Molani M A, Balu D, Ellis A K. Serum troponin T levels predicts coronary angigraphic findings in patients with unstable angina. Circulation 1995; 92: 1–679, (Abstract)
   PubMed Web of Science ®Google Scholar
• Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79(3)491–4
   PubMedGoogle Scholar
• Fragmin during instability in coronary artery disease (FRISC) study group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561–68
   PubMed Web of Science ®Google Scholar
• Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long term antithrombotic protection. J Am Coll Cardiol 1997; 29: 43–8
   PubMed Web of Science ®Google Scholar
• Hamm C W, Heeschen C, Goldmann B, et al. Troponin T predicts the benefit of abciximab in patients with unstable angina in the CAPTURE study. Eur Heart J 1998; 19: 631, (Abstract supplement)
   Google Scholar
• Anderson H V, Cannon C P, Stone P H, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26(7)1643–50
   PubMedGoogle Scholar
• Boden W E, RA O R, Crawford M H, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338(25)1785–92
   PubMed Web of Science ®Google Scholar
• Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol 1997; 80(5A)61E–63E
   PubMedGoogle Scholar
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875)821–8
   PubMed Web of Science ®Google Scholar
• Pfeffer M A, Braunwald E, Moye L A, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10)669–77
   PubMed Web of Science ®Google Scholar
• Rao A C, Collinson P O, Canepa-Anson R, Joseph S P. Troponin T measurement after myocardial infarction can identify left ventricular ejection of less than 40%. Heart 1998; 80(3)223–5
   PubMedGoogle Scholar